Reference is made to the stock exchange release published by Arctic Bioscience 23 February 2022 regarding Board approval of share capital increase related to the exercise of share options and corresponding issuance of new shares in Arctic Bioscience.
The share capital increase has now been registered with the Norwegian Register of Business Enterprises. As a result, the new share capital of Arctic Bioscience has increased from 2,429,953.90 to 2,437,571.90, divided into 24,375,719 shares, each having a nominal value of NOK 0.10.
For further information, please contact
Christer L. Valderhaug, CEO – Arctic Bioscience
+47 920 84 601, firstname.lastname@example.org
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing nutraceutical products based on herring roe oil. Herring roe oil contains lipids that are essential to maintain cell membranes, contributing to normal functioning of brain, heart, and vision. Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients to other companies making dietary supplements, and as finished goods under the Romega brand. The strategy is to switch sales from bulk to finished goods and focus markets are USA and China.
The company is developing HRO350 – a novel investigational drug candidate with herring roe as raw material. HRO350 is being developed for treatment of mild-to -moderate psoriasis. This is a large patient group in need of new effective medicines. Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.